TOX/See multi-Drugscreen Panel 8-test (THC/COC/AMP1000/PCP/BAR/BZO/MOR300/MTD)

Products	TOX/See multi-Drugscreen Panel 8-test (THC/COC/AMP1000/PCP/BAR/BZO/MOR300/MTD)
Company	Bio-Rad Laboratories
Item	TOX/See multi-Drugscreen Panel 8-test (THC/COC/AMP1000/PCP/BAR/BZO/MOR300/MTD)
Features	ComprehensiveTests for as many as 9 drugs per cassette EfficientOne-step test protocol FastResults in as few as 3 minutes
Description	TOX/See™ is a 1-step, hand-held, point-of-care device for the qualitative detection of drug or drug metabolites in human urine. The TOX/See device can detect up to nine of the most commonly abused drugs in 3 to 8 minutes and requires only a few drops of urine. Each TOX/See cassette is individually packaged to maximize convenience and ease of use. TOX/See features integrated test controls, easy-to-read results, and an 18-month shelf life at room temperature. The completed test card can be photocopied and archived for health and legal records. The straightforward test protocol is designed for use by all levels of staff in hospitals, emergency departments, correctional facilities, juvenile facilities, police departments, workplaces, and recovery and rehabilitation programs.
Info	Bio-Rad Laboratories Customer Service: 1-800-2-BIORAD Web site: http://www.bio-rad.com

TAG: TOX See multi Drugscreen Panel test THC COC AMP1000 PCP BAR BZO MOR300 MTD

Utilized for capsulotomies, nucleus dislocating, and other intraocular applications. Formed (bent) cystitomes are angled to conform to the convexity of the lens, providing easier access to the anteri

Left. 23 gauge thin wall irrigation. 25 gauge thin wall aspiration. Angled 20 degree shaft 10 mm from tip to bend. Irrigation tip set 0.5 mm behind aspiration tip. Side taper irrigation-aspiration th

This specially designed 23 gauge spoon-shaped cannula is connected to a balanced salt solution bottle and with a low-flow of fluid, is designed to allow a controlled cleaning of the stromal interface

Reliance pneumatic stools come with five legs for extra stability. Adjustable height range of 18" to 25" (total vertical travel 6"). 2" ball bearing swivel hard rubber castors. Comfortable, durable a

Medicine Products:

Irrigating Cystitomes Gills-Welsh Irrigating-Aspirating Cannula with Flat Olive Tip Lasik Irrigation Cannula Reliance Stools, Model 5340

(Date:12/3/2008)... The American College of...Medicine (IOM) for its committee report on residen..., by the IOM Committee on Optimizing Graduate Medi... Improve Patient Safety. , , ACS agrees w...ons in the mandated 80-hour work week (averaged ov...

(Date:12/3/2008)...e and Half Times Greater Than Entire U.S. Economy ...-- If the federal government stopped the Medicare ...g no more payroll taxes and allowing no more accru...llion to those who have already earned these benef...er for Policy Analysis (NCPA). , , "The n...

(Date:12/3/2008)..., Dec. 3 The Belmont(R) Rapid Infu...Support Hospitals to treat wounded,soldiers, civi...ith helping to,save the life of an Omaha, NE Poli...mes during a traffic stop. One of the bullets,hit...uring a major artery. , "Injury to this are...

(Date:12/3/2008)...respond at first not helped by maintenance treatme...ealthDay News) -- Maintenance therapy using low-do...ed chronic hepatitis C who haven,t responded to an.... , The study also showed a surprising health d...rse of four years. , "This course of treatment ...

Breaking Medicine News(10 mins):Health News:American College of Surgeons Comments on Institute of Medicine Report on Resident Duty Hours 2 Health News:Medicare, Social Security Owe Up to $52 Trillion to Current Retirees and Workers 2 Health News:Belmont(R) Rapid Infuser Helps Save Officer's Life 2 Health News:Hepatitis C Therapy Useless for Some 2

[0] American College of Surgeons Comments on Institute of Medicine Report on Resident Duty Hours [0] Medicare, Social Security Owe Up to $52 Trillion to Current Retirees and Workers [0] Belmont(R) Rapid Infuser Helps Save Officer's Life [0] Hepatitis C Therapy Useless for Some

... the creation of the cells that help build the bod...erived from human embryonic stem cells, and have ...ls have shown promise in lab animal treatment of d...team led by Shi-Jiang Lu of Advanced Cell Technolo...

...any Advanced Cell Technology, is obviously thril...ts or stem cells that repair arteries and regenera...ls made from human embryos can proceed on to he...and appear to start repairs.ACT claims to have dev...

...eclined over the century from 972 in 1901 to 927 i...n 2001. In contrast, the child sex ratio for the ...ousand boys against 945 recorded in 1991 Census. ...cerned, it is 1.01 male (s)/females as in 2006. S...

...et captain Brian Lara has thrown a punch at the We...a cancer center named after him. He commended the...ction and management of the Brian Lara Cancer Cent...d use of technology," adding that these had "misse...

Other Medicine News:Health News:Hemangioblasts Aiding Eye Damage Repair 2

Hemangioblasts New Tool Of Stem Cell Technology Hemangioblasts Aiding Eye Damage Repair Declining Sex Ratio Brian Lara Opens Cancer Center Named After Him

(Date:12/2/2008)...Ill., Dec. 2 Horizon Therapeutics,..., today announced that two pivotal,Phase 3 trials...date, HZT-501,met all primary endpoints. HZT-501...duct containing ibuprofen and famotidine, demonstr... incidence of non-steroidal,anti-inflammatory dru...

(Date:12/1/2008)...E, Md., Dec. 1 Vanda Pha...ation in The Lancet , one of the world,s leading ...s novel circadian regulator, experimental compound...tnam et al(1) is entitled "Melatonin agonist tasim...p-time shift: two randomised controlled multicentr...

(Date:12/1/2008)...l with Hypophosphatasia Treated With ENB-0040 at C...ipeg , , MONTREAL, Dec. 1 E... focused on developing novel therapeutics for seri... infant patient in its clinical program for hypoph...me Replacement Therapy (ERT) with ENB-0040 for the...

(Date:12/1/2008)...TGARD, Denmark, December 1 /PRNewswire-FirstCall/ ...7 with the intent to procure an MVA-based,third ...rnment Services,Canada, on behalf of the Canadian...ntract to Bavarian Nordic for the delivery of IMVA...to use IMVAMUNE(R) as part of the,country,s bio-p...

Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2 Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3 Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4 Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2 Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3 Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4 Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2 Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3 Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4 Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5 The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2 The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3 Highmark Blue Cross Blue Shield United Concordia and Catholic Charities Join Forces to Offer Free Health Dental Services This Saturday 24194 1 Highmark Blue Cross Blue Shield United Concordia and Catholic Charities Join Forces to Offer Free Health Dental Services This Saturday 24194 2 Norgen Biotek Corp Launches Four New Kits for the Purification of RNA and DNA from Plants and Fungi 6644 1 Norgen Biotek Corp Launches Four New Kits for the Purification of RNA and DNA from Plants and Fungi 6644 2 Alzheimers Research Brings Progress Setbacks 24192 1 Alzheimers Research Brings Progress Setbacks 24192 2 Alzheimers Research Brings Progress Setbacks 24192 3 Alzheimers Research Brings Progress Setbacks 24192 4 minSURG 28TM 29 Corporation Launches International Division 24190 1 minSURG 28TM 29 Corporation Launches International Division 24190 2

[0] Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints [0] Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet [0] Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease [0] The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness

...ed Statistical Significance, FRAZER, Pa., May 01.... Phase 3 clinical trial presented today at the 59...rology in Boston highlights,data demonstrating t...s beneficial for the treatment of breakthrough pai...ady taking opioids around-the,clock to manage th...

...y 1, 2007 - Genentech, Inc. (NYSE:DNA),and Biogen ...ata,from a Phase II clinical study of Rituxan(R) (...ltiple sclerosis (RRMS) were,presented today at th...d in Boston. Rituxan is a therapeutic antibody tha...-cells., "There remains a great need for safe and ...

Other Medicine Technology:Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 2 Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 3 Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 4 Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 5 Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 6 Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 7 Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2 Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3 Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4 Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5 Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6

Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology